What is the standard testosterone injection regimen (dose and frequency) for treating primary testicular hypogonadism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Standard Testosterone Injection Regimen for Primary Testicular Hypogonadism

For primary testicular hypogonadism, administer testosterone enanthate or cypionate 75-100 mg intramuscularly weekly, or 150-200 mg every 2 weeks, targeting mid-normal serum testosterone levels (450-600 ng/dL). 1

Dosing Algorithm

The choice between weekly and bi-weekly dosing depends on symptom stability and tolerability:

Weekly Dosing (Preferred for Stability)

  • 75-100 mg IM weekly provides more stable testosterone levels with less peak-trough variation 1
  • Reduces fluctuations in mood, libido, and energy that some patients experience with longer intervals 2
  • Particularly beneficial for patients with:
    • Low sex hormone-binding globulin (SHBG)
    • Symptoms of peak-related side effects (acne, fluid retention, mood swings)
    • Late-cycle symptom recurrence (fatigue, reduced libido) 3

Bi-Weekly Dosing (Standard Alternative)

  • 150-200 mg IM every 2 weeks remains a convenient and effective option 1
  • Acceptable when patients maintain stable symptoms throughout the dosing interval
  • The FDA label specifies 50-400 mg every 2-4 weeks, though smaller, more frequent doses better maintain physiologic levels 4

Twice-Weekly Dosing (For Refractory Cases)

  • Consider 50 mg IM twice weekly when weekly dosing still produces symptomatic cycling 3
  • Provides the smoothest testosterone exposure pattern
  • Useful when hematocrit elevation, estradiol-related symptoms, or blood pressure changes occur with less frequent dosing

Important Caveats

The traditional regimen of 200-300 mg every 2-3 weeks is outdated. While historically standard 2, this approach produces supraphysiologic peaks and subtherapeutic troughs. Smaller doses at more frequent intervals maintain testosterone in the normal range more consistently 2, 5.

Measure testosterone levels midway between injections to assess adequacy 1, 6. If testosterone is >700 ng/dL or <400 ng/dL at this midpoint, adjust dose or frequency 6.

Monitoring Requirements

Essential safety monitoring includes:

  • Hematocrit: Check at baseline, 3-6 months, then annually. Stop therapy if >54% until it decreases; evaluate for hypoxia/sleep apnea before reinitiating at reduced dose 6, 7

  • Testosterone levels: Assess at 3-6 months after initiation, targeting mid-normal range (450-600 ng/dL) 7, 8

  • Prostate monitoring: For men ≥40 years with baseline PSA >0.6 ng/mL, check PSA and digital rectal exam at baseline, 3-6 months, then per screening guidelines 6

  • Clinical response: Evaluate symptoms at 3-6 months and annually 6, 7

Contraindications

Do not initiate testosterone therapy in patients with:

  • Hematocrit >50% (relative contraindication; >54% absolute) 6, 7
  • Prostate cancer or breast cancer 1
  • Uncontrolled severe heart failure 1
  • Untreated obstructive sleep apnea 1

Key Clinical Pitfall

The most common error is choosing injection frequency by habit rather than clinical reasoning. 3 Document the specific ester, dose, concentration, injection interval, timing of last injection, and timing of bloodwork—without this context, testosterone results are uninterpretable. If a patient reports symptom cycling, early peak-related symptoms, or late-cycle hypogonadal symptoms, the issue is often dose timing rather than inadequate total dose. Consider dose redistribution (more frequent, smaller injections) before dose escalation 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.